Yves Fradet
Centre hospitalier universitaire de Québec · 691 works · 28,213 citations · h-index 80
Top works
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies.
- PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata
- Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.
- Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
- PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome
- PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy
- Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
- Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers
- A Phase III, Multicenter Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Superficial Papillary Lesions in Patients With Bladder Cancer
- Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
- A Comparison of Hexaminolevulinate Fluorescence Cystoscopy and White Light Cystoscopy for the Detection of Carcinoma In Situ in Patients With Bladder Cancer: A Phase III, Multicenter Study
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.
- uPM3, a new molecular urine test for the detection of prostate cancer
- Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
- Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes